Perspectives on diabetic retinopathy

被引:206
作者
Aiello, LM [1 ]
机构
[1] Joslin Diabet Ctr, Beetham Eye Inst, Boston, MA 02215 USA
[2] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA
关键词
D O I
10.1016/S0002-9394(03)00219-8
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PURPOSE: To review the evolution of the understanding of diabetic retinopathy (DR) and methods of treating DR, the present clinically relevant practice for eye disease in patients with diabetes mellitus, and trends in clinical patient care over the next 3 to 5 years. DESIGN: Tabular review and presentation of clinical trials contributing to the understanding and treatment of DR and the author's philosophy of care for the patient with diabetes. RESULTS: Diabetic retinopathy is a microvascular complication of diabetes mellitus that is a significant cause of new,onset blindness. The Diabetic Retinopathy Study was the first multicentered, randomized, clinical trial in ophthalmology. This study provided the scientific evidence for treatment of DR with scatter (panretinal) photocoagulation, and led to the funding of other multicentered clinical trials, including the Early Treatment Diabetic Retinopathy Study, which greatly elucidated the natural history of DR and firmly established laser photocoagulation as treatment for proliferative diabetic retinopathy (PDR) and diabetic macular edema. The Diabetes Control and Complications Trial and United Kingdom Prospective Diabetes Study established the value of intensive glycemic control in reducing the risk of onset and progression of DR and other microvascualr complications of diabetes. CONCLUSIONS: Severe vision loss and moderate vision loss from diabetes are essentially preventable with timely detection and treatments, careful long,term follow-up and comprehensive diabetes mellitus care firmly based on clinical evidence. Future treatments, as outgrowths of further understanding of the biochemical basis of the disease, will aim at curing or preventing retinal complications from diabetes. (Am J Ophthalmol 2003;136: 122-135. (C) 2003 by Elsevier Inc. All rights reserved.).
引用
收藏
页码:122 / 135
页数:14
相关论文
共 99 条
[1]   INCREASED VASCULAR ENDOTHELIAL GROWTH-FACTOR LEVELS IN THE VITREOUS OF EYES WITH PROLIFERATIVE DIABETIC-RETINOPATHY [J].
ADAMIS, AP ;
MILLER, JW ;
BERNAL, MT ;
DAMICO, DJ ;
FOLKMAN, J ;
YEO, TK ;
YEO, KT .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1994, 118 (04) :445-450
[2]   Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate [J].
Adamis, AP ;
Shima, DT ;
Tolentino, MJ ;
Gragoudas, ES ;
Ferrara, N ;
Folkman, J ;
DAmore, PA ;
Miller, JW .
ARCHIVES OF OPHTHALMOLOGY, 1996, 114 (01) :66-71
[3]  
Aiello LM, 2000, OPHTHALMOL CLIN N AM, V13, P213
[4]  
AIELLO LM, 1968, PHS PUBL, V1890, P437
[5]   Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor [J].
Aiello, LP ;
Bursell, SE ;
Clermont, A ;
Duh, E ;
Ishii, H ;
Takagi, C ;
Mori, F ;
Ciulla, TA ;
Ways, K ;
Jirousek, M ;
Smith, LEH ;
King, GL .
DIABETES, 1997, 46 (09) :1473-1480
[6]   SUPPRESSION OF RETINAL NEOVASCULARIZATION IN-VIVO BY INHIBITION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR (VEGF) USING SOLUBLE VEGF-RECEPTOR CHIMERIC PROTEINS [J].
AIELLO, LP ;
PIERCE, EA ;
FOLEY, ED ;
TAKAGI, H ;
CHEN, H ;
RIDDLE, L ;
FERRARA, N ;
KING, GL ;
SMITH, LEH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (23) :10457-10461
[7]   VASCULAR ENDOTHELIAL GROWTH-FACTOR IN OCULAR FLUID OF PATIENTS WITH DIABETIC-RETINOPATHY AND OTHER RETINAL DISORDERS [J].
AIELLO, LP ;
AVERY, RL ;
ARRIGG, PG ;
KEYT, BA ;
JAMPEL, HD ;
SHAH, ST ;
PASQUALE, LR ;
THIEME, H ;
IWAMOTO, MA ;
PARK, JE ;
NGUYEN, HV ;
AIELLO, LM ;
FERRARA, N ;
KING, GL .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (22) :1480-1487
[8]   Role of vascular endothelial growth factor in diabetic vascular complications [J].
Aiello, LP ;
Wong, JS .
KIDNEY INTERNATIONAL, 2000, 58 :S113-S119
[9]  
AIRAKSINEN KEJ, 1990, DIABETES RES CLIN EX, V14, P149
[10]  
[Anonymous], 1995, Arch Ophthalmol, V113, P1144